Cost-effectiveness analysis of capecitabine versus active monitoring in stable or responding metastatic colorectal cancer after 16 weeks of first-line therapy
Compared to active monitoring, maintenance treatment with capecitabine alone was not cost-effective in stable or responding mCRC after 16 weeks of first-line therapy.
Authors
- Zhiqiang Tong
- Ruihong Yao
- Lu Zhong (ORCID: https://orcid.org/0009-0004-0910-0515)
- Tong Liu (ORCID: https://orcid.org/0000-0002-1389-7051)
- Mei Dong (ORCID: https://orcid.org/0000-0002-2944-6853)
Institutions
- Harbin Medical University (CN)
- Third Affiliated Hospital of Harbin Medical University (CN)
Publication Details
- Journal
- Annals of Medicine
- Published
- 2025-07-05
- DOI
- https://doi.org/10.1080/07853890.2025.2529573
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00